Vertex continues to develop type 1 diabetes therapy, zimislecel, which is being investigated in a Phase III trial.

Intermittent fasting might help manage Type 2 diabetes by improving blood sugar control, reducing insulin resistance, and ...

Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to ...

The Oklahoma House passed Bill 1380 to reduce insulin costs, now heading to the Senate. The bill aims to make insulin ...

Despite a $400 million impairment charge, analysts say the removal of a drug-device combo from its portfolio is not a huge ...

Vertex Pharmaceuticals will not advance clinical trials of a treatment for Type 1 diabetes after efficacy data failed to support further clinical advancement.

Oppenheimer lowered the firm’s price target on Biomea Fusion (BMEA) to $10 from $50 and keeps an Outperform rating on the shares after the ...

CMO Jordan Pinsker said Tandem hopes to expand Medicare coverage of its automated insulin delivery systems with results of a ...